Hadassah

Hadassah Inoculates First Patient in Trial of Israeli-Made COVID-19 Vaccine

Tuesday, Nov 3 2020

Anar Ottolenghi, a 34-year-old doctoral student in immunology, was one of the first Israelis to be inoculated on Sunday morning as part of the Phase I clinical trial of an Israeli-made coronavirus vaccine at Hadassah Hospital Ein Kerem.

“I feel good, excited,” Ottolenghi said. “I want to encourage as many people as possible to join the experiment and help the entire public.”

The Israeli vaccine, known as “Brilife,” was developed by the Israel Institute for Biological Research (IIBR), and Sunday marked the launch of its Phase I clinical trial, in which 80 healthy volunteers between the ages of 18 and 55 will participate—40 at Hadassah and 40 at Sheba Medical Center in Tel Hashomer. Each volunteer will receive an injection, with some receiving the vaccine and some receiving a placebo.

Volunteers will be monitored over the course of three weeks to assess the vaccine’s safety. Researchers will also examine whether volunteers develop antibodies to the coronavirus. If Phase I yields successful results, Phase II will probably begin in December with 960 healthy volunteers at medical centers throughout the country. Phase II will continue to monitor the vaccine’s safety and gauge effectiveness and also pinpoint appropriate doses. If the first two phases are successful, a Phase III trial/p of 30,000 volunteers will begin in April or May.

Prof. Shmuel Shapira, head of IIBR and former deputy director general of Hadassah Ein Kerem, noted, “IIBR has developed many vaccines.” He continued, “Six years before this crisis, we had already started preparing for such an event.”

Prime Minister Benjamin Netanyahu commented, “The true exit from the coronavirus crisis is in the development of vaccines. With God’s help, we will have a vaccine made here in Israel.”

Read the full story in The Jerusalem Post.

Updates:

Hadassah Ein Kerem just reported that two more Israelis were vaccinated at the hospital on Monday, November 2, 2020: Jerusalemite Effi, age 26, a computer scientist originally from England, and Eli Ein-Dor, age 50, a programmer with the Israeli Port Authority.

“I am neither a doctor nor a nurse, so in my eyes, the best way to contribute is by participating in the trial,” Effi said.  Read more about Effi

Sunday,  November 8, 2020 Update:
Four women receive Brilife COVID vaccination, as Hadassah trials continue

 

Learn more about the Hadassah Medical Organization.

Related Stories

alt_text

Tuesday, Nov 24 2020

[Hadassah On Call Podcast] COVID's Long-Term Health Impact, an Insider's Perspective

It's no longer enough to find a COVID-19 cure. Each day, we're discovering long-term complications for those who have recovered from the virus.

READ MORE ›
alt_text

Monday, Nov 23 2020

Eye-Opening Advances: Hadassah Transports Us Into the Future of Eye Care

As Prof. Itai Chowers, head of the Hadassah Medical Organization’s Division of Ophthalmology, told his international audience during a November 19 webinar, “Hadassah has been using cutting-edge technologies to fight eye disease for over 103 years.”

READ MORE ›
alt_text

Monday, Nov 16 2020

Hadassah Gastroenterologists Remove Padlock From Child’s Stomach

Without resorting to surgery, Hadassah Hospital Ein Kerem gastroenterologists removed a padlock from 6-year-old Tommy’s stomach.

READ MORE ›
alt_text

Monday, Nov 16 2020

Hadassah Hospital Staff Host Circumcision Celebration

When Hadassah Hospital Ein Kerem staff members realized that a first-time mother did not have the means to organize a brit mila (circumcision celebration) following the birth of her son, they organized one for her.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

More ›

Show More